Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model

Biochemical Pharmacology

Volumn 78, Issue 6, 2009, Pages 617-624

  Wu, Chao ^a   Jiang, Xi Ling ^a   Shen, Hong Wu ^a   Yu, Ai Ming ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

CYP2D6; Harmaline; Pharmacogenetics; Pharmacokinetics; Transgenic mouse

Indexed keywords

CYTOCHROME P450 2D6; DRUG METABOLIZING ENZYME; HARMALINE; O DEMETHYLASE;

ADULT ANIMAL; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE; DRUG EXPOSURE; DRUG METABOLISM; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; HYPOTHERMIA; IN VITRO STUDY; IN VIVO STUDY; KINETICS; LIVER CELL; MALE; METABOLITE; MOUSE; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN DEPLETION; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; BEHAVIOR; CYTOCHROME P-450 CYP2D6; GENOTYPE; HARMALINE; HEPATOCYTES; HUMANS; MALE; MICE; MICE, TRANSGENIC; MICROSOMES, LIVER; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 67651171204     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.05.011     Document Type: Article

References (40)

1. Yu A.M., Idle J.R., and Gonzalez F.J. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev 36 2 (2004) 243-277
2. Zanger U.M., Raimundo S., and Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369 1 (2004) 23-37
3. Sellers E.M., and Tyndale R.F. Mimicking gene defects to treat drug dependence. Ann N Y Acad Sci 909 (2000) 233-246
4. Maurer H.H., Kraemer T., Springer D., and Staack R.F. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit 26 2 (2004) 127-131
5. Theobald D.S., and Maurer H.H. Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series). Biochem Pharmacol 73 2 (2007) 287-297
6. Ramamoorthy Y., Yu A.M., Suh N., Haining R.L., Tyndale R.F., and Sellers E.M. Reduced (±)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem Pharmacol 63 12 (2002) 2111-2119
7. Yu A.M. Indolealkylamines: biotransformations and potential drug-drug interactions. Aaps J 10 2 (2008) 242-253
8. Narimatsu S., Yonemoto R., Saito K., Takaya K., Kumamoto T., Ishikawa T., et al. Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes. Biochem Pharmacol 71 9 (2006) 1377-1385
9. Narimatsu S., Yonemoto R., Masuda K., Katsu T., Asanuma M., Kamata T., et al. Oxidation of 5-methoxy-N,N-diisopropyltryptamine in rat liver microsomes and recombinant cytochrome P450 enzymes. Biochem Pharmacol 75 3 (2008) 752-760
10. Sauer C., Peters F.T., Schwaninger A.E., Meyer M.R., and Maurer H.H. Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine. Biochem Pharmacol 77 3 (2009) 444-450
11. Staack R.F., Paul L.D., Springer D., Kraemer T., and Maurer H.H. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP), In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes. Biochem Pharmacol 67 2 (2004) 235-244
12. Rutter J.L. Symbiotic relationship of pharmacogenetics and drugs of abuse. Aaps J 8 1 (2006) E174-E184
13. Lamchouri F., Settaf A., Cherrah Y., El Hamidi M., Tligui N., Lyoussi B., et al. Experimental toxicity of Peganum harmala seeds. Ann Pharm Fr 60 2 (2002) 123-129
14. McKenna D.J. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol Ther 102 2 (2004) 111-129
15. Lee C.S., Han E.S., Jang Y.Y., Han J.H., Ha H.W., and Kim D.E. Protective effect of harmalol and harmaline on MPTP neurotoxicity in the mouse and dopamine-induced damage of brain mitochondria and PC12 cells. J Neurochem 75 2 (2000) 521-531
16. Moura D.J., Richter M.F., Boeira J.M., Pegas Henriques J.A., and Saffi J. Antioxidant properties of beta-carboline alkaloids are related to their antimutagenic and antigenotoxic activities. Mutagenesis 22 4 (2007) 293-302
17. Hilber P., and Chapillon P. Effects of harmaline on anxiety-related behavior in mice. Physiol Behav 86 1-2 (2005) 164-167
18. Berrougui H., Martin-Cordero C., Khalil A., Hmamouchi M., Ettaib A., Marhuenda E., et al. Vasorelaxant effects of harmine and harmaline extracted from Peganum harmala L. seeds in isolated rat aorta. Pharmacol Res 54 2 (2006) 150-157
19. Monsef H.R., Ghobadi A., Iranshahi M., and Abdollahi M. Antinociceptive effects of Peganum harmala L. alkaloid extract on mouse formalin test. J Pharm Pharm Sci 7 1 (2004) 65-69
20. Miwa H. Rodent models of tremor. Cerebellum 6 1 (2007) 66-72
21. Martin F.C., Thu Le A., and Handforth A. Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications. Mov Disord 20 3 (2005) 298-305
22. Wilms H., Sievers J., and Deuschl G. Animal models of tremor. Mov Disord 14 4 (1999) 557-571
23. Frison G., Favretto D., Zancanaro F., Fazzin G., and Ferrara S.D. A case of beta-carboline alkaloid intoxication following ingestion of Peganum harmala seed extract. Forensic Sci Int 179 2-3 (2008) e37-e43
24. Brush D.E., Bird S.B., and Boyer E.W. Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances. J Toxicol Clin Toxicol 42 2 (2004) 191-195
25. Sklerov J., Levine B., Moore K.A., King T., and Fowler D. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. J Anal Toxicol 29 8 (2005) 838-841
26. Lorenz D., and Deuschl G. Update on pathogenesis and treatment of essential tremor. Curr Opin Neurol 20 4 (2007) 447-452
27. Ho B.T., Estevez V., Fritchie G.E., Tansey L.W., Idanpaan-Heikkila J., and McIsaac W.M. Metabolism of harmaline in rats. Biochem Pharmacol 20 6 (1971) 1313-1319
28. Yu A.M., Idle J.R., Krausz K.W., Kupfer A., and Gonzalez F.J. Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther 305 1 (2003) 315-322
29. Corchero J., Granvil C.P., Akiyama T.E., Hayhurst G.P., Pimprale S., Feigenbaum L., et al. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol 60 6 (2001) 1260-1267
30. Abdel-Fattah A.F., Matsumoto K., Gammaz H.A., and Watanabe H. Hypothermic effect of harmala alkaloid in rats: involvement of serotonergic mechanism. Pharmacol Biochem Behav 52 2 (1995) 421-426
31. Granvil C.P., Yu A.M., Elizondo G., Akiyama T.E., Cheung C., Feigenbaum L., et al. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metab Dispos 31 5 (2003) 548-558
32. Dayneka N.L., Garg V., and Jusko W.J. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21 4 (1993) 457-478
33. Gonzalez F.J., and Yu A.M. Cytochrome P450 and xenobiotic receptor humanized mice. Annu Rev Pharmacol Toxicol 46 (2006) 41-64
34. Njung'e K., and Handley S.L. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 38 1 (1991) 63-67
35. Borsini F., Podhorna J., and Marazziti D. Do animal models of anxiety predict anxiolytic-like effects of antidepressants?. Psychopharmacology (Berl) 163 2 (2002) 121-141
36. Cryan J.F., and Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 4 9 (2005) 775-790
37. Callaway J.C. Fast and slow metabolizers of Hoasca. J Psychoactive Drugs 37 2 (2005) 157-161
38. Gibbs J.P., Hyland R., and Youdim K. Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism. Drug Metab Dispos 34 9 (2006) 1516-1522
39. Tang H., Hussain A., Leal M., Mayersohn M., and Fluhler E. Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 35 10 (2007) 1886-1893
40. Kirchheiner J., Fuhr U., and Brockmoller J. Pharmacogenetics-based therapeutic recommendations-ready for clinical practice?. Nat Rev Drug Discov 4 8 (2005) 639-647